FABP1 and metabolic dysfunction-associated steatohepatitis: FABP levels may vary according to disease severity as FABP1 protein levels were overexpressed in obese patients with steatosis (n = 10) compared to obese controls (n = 10), but decreased in NASH patients with mild fibrosis (n = 10) and declining further in NASH with advanced fibrosis (n = 10) [36].